Deferasirox
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Aminosalicylic acid
Antimycobacterial · Anti-tuberculosis agent
Also known as 5-aminosalicylic acid, 5-ASA
AntimycobacterialAnti-tuberculosis agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
8 major
SEVERE in our sources
PREGNANCY
Manufacturer advises avoid unless essential—toxicity in animal studies (highest risk during first trimester).
FDA category + note
Top interactionssee all 8 →
- DeferasiroxSevereDatabaseDDInter
- LeflunomideSevereDatabaseDDInter
- LomitapideSevereDatabaseDDInter
- MipomersenSevereDatabaseDDInter
Mechanism
The provided excerpts do not describe the mechanism of action for aminosalicylic acid as an antimycobacterial agent. Instead, 5-aminosalicylic acid is identified as an anti-inflammatory agent for inflammatory bowel disease. It primarily inhibits the proinflammatory NF-κB signaling pathway, suppressing T-cell responses and the production of cytokines such as IL-1, -6, -8, -11, -12, and TNF to reduce inflammation.
Indications
Multiple-drug resistant tuberculosis, in combination with other drugsCombination therapy after bedaquiline
Dosing
- Adult
- 4 g every 8 hours for a usual treatment duration of 24 months
- Max dose
- 12 g per day
Side effects
Common
Diarrhoeadizzinessgastrointestinal discomfortgastrointestinal disordershypersensitivitynauseaskin reactionsvestibular syndromevomiting
Serious
- Agranulocytosis
- anaemia
- crystalluria
- gastrointestinal haemorrhage
- headache
- hepatic disorders
- hypoglycaemia
- hypothyroidism
- leucopenia
- methaemoglobinaemia
- peripheral neuropathy
- taste metallic
- tendon pain
- thrombocytopenia
- visual impairment
- weight decreased
Pregnancy & lactation
Pregnancy
Manufacturer advises avoid unless essential—toxicity in animal studies (highest risk during first trimester).
Drug interactions
Leflunomide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Lomitapide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Mipomersen
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Nitrous Acid
Severe
Database
Clinical effect not specified
Source: DDInter
Pexidartinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Prilocaine
Severe
Database
Clinical effect not specified
Source: DDInter
Teriflunomide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
4 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Other Antimycobacterial drugs
Ask House about Aminosalicylic acid
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Katzung, BNF, Nelson·Verified: 2026-05-10 · House clinical team